Pharmaceutical

ESCMID 2024: Drug resistance in fungi – a growing issue

Emerging research from the ESCMID Global 2024 conference suggests that antifunga...

EyePoint Pharmaceuticals gets grant for treatment of oc...

Discover the groundbreaking patent by EyePoint Pharmaceuticals Inc for treating ...

Pacira BioSciences gets grant for method for treating s...

Discover the innovative method by Pacira BioSciences Inc to treat spasticity in ...

Inovio Pharmaceuticals gets grant for electroporation d...

Discover the latest patent from Inovio Pharmaceuticals Inc for an innovative ele...

Merus gets grant for treatment of clec12a positive canc...

Discover a groundbreaking patent for treating CLEC12A positive cancer with bispe...

Precision Biosciences gets grant for engineered meganuc...

Unlock the potential of genetic modification with Precision Biosciences Inc's pa...

Corcept Therapeutics gets grant for method of preparing...

Discover the latest patent from Corcept Therapeutics Inc on methods for preparin...

Novartis and PeptiDream expand peptide discovery deal

Novartis and Japanese biopharmaceutical company PeptiDream have expanded their p...

ESCMID 2024: The infectious consequences of climate change

Dengue fever is now found in over 120 countries compared to nine that experience...

Pfizer and Genmab’s Tivdak wins full FDA approval for c...

The FDA granted accelerated approval for the drug back in September 2021 followi...

Ionis Pharmaceuticals gets grant for modified oligonucl...

Discover how Ionis Pharmaceuticals' patent for modified oligonucleotides offers ...

ESCMID 2024: Using AI in infection prevention and control

Artificial intelligence tools can be used for infection control through facial r...

Pioneer Institute study finds IRA discourages non-opioi...

The IRA adds another hurdle to an already challenging research landscape, accord...

The privileged status of orphan medicines in Germany

In Germany, new measures have come into effect as part of the GKV-FinStG Act in ...

Top 20 biopharma kick off 9.6% market cap surge in Q1 2...

The top 20 biopharmaceutical companies witnessed a promising first quarter (Q1) ...

Cerevance raises $47m to fund Phase III trial for lead ...

The Series B extension proceeds will fund Phase III trial for Cerevance’s lead C...